Literature DB >> 19054514

Cardiovascular risk factor control and outcomes in peripheral artery disease patients in the Reduction of Atherothrombosis for Continued Health (REACH) Registry.

Patrice P Cacoub1, Maria Teresa B Abola, Iris Baumgartner, Deepak L Bhatt, Mark A Creager, Chiau-Suong Liau, Shinya Goto, Joachim Röther, P Gabriel Steg, Alan T Hirsch.   

Abstract

OBJECTIVES: To examine differences in risk factor (RF) management between peripheral artery disease (PAD) and coronary artery (CAD) or cerebrovascular disease (CVD), as well as the impact of RF control on major 1-year cardiovascular (CV) event rates.
METHODS: The REACH Registry recruited >68000 outpatients aged >or=45 years with established atherothrombotic disease or >or=3 RFs for atherothrombosis. The predictors of RF control that were evaluated included: (1) patient demographics, (2) mode of PAD diagnosis, and (3) concomitant CAD and/or CVD.
RESULTS: RF control was less frequent in patients with PAD (n=8322), compared with those with CAD or CVD (but no PAD, n=47492) [blood pressure; glycemia; total cholesterol; smoking cessation (each P<0.001)]. Factors independently associated with optimal RF control in patients with PAD were male gender (OR=1.9); residence in North America (OR=3.5), Japan (OR=2.5) or Latin America (OR=1.5); previous coronary revascularization (OR=1.3); and statin use (OR=1.4); whereas prior leg amputation was a negative predictor (OR=0.7) (P<0.001). Optimal RF control was associated with fewer 1-year CV ischemic symptoms or events.
CONCLUSIONS: Patients with PAD do not achieve RF control as frequently as individuals with CAD or CVD. Improved RF control is associated with a positive impact on 1-year CV event rates.

Entities:  

Mesh:

Year:  2008        PMID: 19054514     DOI: 10.1016/j.atherosclerosis.2008.10.023

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  45 in total

Review 1.  Proteomic and metabolomic profiles in atherothrombotic vascular disease.

Authors:  Roxana Martinez-Pinna; Coral Barbas; Luis Miguel Blanco-Colio; Jose Tunon; Priscila Ramos-Mozo; Juan Antonio Lopez; Olivier Meilhac; Jean-Baptiste Michel; Jesus Egido; José Luis Martin-Ventura
Journal:  Curr Atheroscler Rep       Date:  2010-05       Impact factor: 5.113

2.  One-year costs associated with cardiovascular disease in Canada: Insights from the REduction of Atherothrombosis for Continued Health (REACH) registry.

Authors:  Kim G Smolderen; Alan Bell; Yang Lei; Eric A Cohen; P Gabriel Steg; Deepak L Bhatt; Elizabeth M Mahoney
Journal:  Can J Cardiol       Date:  2010-10       Impact factor: 5.223

Review 3.  PAD in women: the ischemic continuum.

Authors:  Amy West Pollak
Journal:  Curr Atheroscler Rep       Date:  2015-06       Impact factor: 5.113

Review 4.  Consideration of Sex Differences in Design and Reporting of Experimental Arterial Pathology Studies-Statement From ATVB Council.

Authors:  Peggy Robinet; Dianna M Milewicz; Lisa A Cassis; Nicholas J Leeper; Hong S Lu; Jonathan D Smith
Journal:  Arterioscler Thromb Vasc Biol       Date:  2018-01-04       Impact factor: 8.311

Review 5.  Limb ischemia: cardiovascular diagnosis and management from head to toe.

Authors:  Sreekanth Vemulapalli; Manesh R Patel; W Schuyler Jones
Journal:  Curr Cardiol Rep       Date:  2015-07       Impact factor: 2.931

Review 6.  Prevention and Management of Urgent/Emergent Limb Ischemia.

Authors:  Graham R McClure; Noel Chan; Eric Kaplovitch; Vinai Bhagirath; Sonia S Anand
Journal:  Curr Cardiol Rep       Date:  2021-03-11       Impact factor: 2.931

7.  Risk-factor profile, drug usage and cardiovascular events within a year in patients with and at high risk of atherothrombosis recruited from Asia as compared with those recruited from non-Asian regions: a substudy of the REduction of Atherothrombosis for Continued Health (REACH) registry.

Authors:  S Goto; Y Ikeda; J C N Chan; P W F Wilson; T Cheng Yeo; C S Liau; M T Abola; G Salette; P G Steg; D L Bhatt
Journal:  Heart Asia       Date:  2011-01-01

Review 8.  Clinical efficacy and safety of cilostazol: a critical review of the literature.

Authors:  Kelly C Rogers; Carrie S Oliphant; Shannon W Finks
Journal:  Drugs       Date:  2015-03       Impact factor: 9.546

9.  Associations between conventional cardiovascular risk factors and risk of peripheral artery disease in men.

Authors:  Michel M Joosten; Jennifer K Pai; Monica L Bertoia; Eric B Rimm; Donna Spiegelman; Murray A Mittleman; Kenneth J Mukamal
Journal:  JAMA       Date:  2012-10-24       Impact factor: 56.272

10.  Long-term survival after initial hospital admission for peripheral arterial disease in the lower extremities.

Authors:  I Vaartjes; G J de Borst; J B Reitsma; A de Bruin; F L Moll; D E Grobbee; M L Bots
Journal:  BMC Cardiovasc Disord       Date:  2009-08-28       Impact factor: 2.298

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.